Mather Group’s Immunovant IMVT Stock Holding History

Mather Group’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.08K	Buy	+32	New	+$1.26K	﹤0.01%	2144

Other funds holding IMVT

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

FIA

FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

Mather Group's IMVT Position: Q3 2026 in Review

Mather Group opened a new position in Immunovant (IMVT) in Q3 2026: 32 shares worth $1.08K. The stake represents ﹤0.01% of the portfolio and ranks #2144 among its holdings.

13 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

Mather Group held 32 shares of Immunovant worth $1.08K as of Q3 2026.
Immunovant was a new Mather Group position in Q3 2026.
Immunovant made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #2144 holding.
13 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.